SPRO logo

SPRO Spero Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$0.83
-0.05 (-5.46%)

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-clas…

Market Cap: $48.14Msperotherapeutics.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
56
2 mentions
—
60d
53
4 mentions
—
90d
53
4 mentions
—
news: 4

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 5Sell 2Strong Sell 0

Revenue

$0.00-100.00%
$0.00$24.51M$49.01M$73.52M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.10
$-0.10–$-0.10
1 analysts
FY2026
$-1.23
$-1.28–$-1.18
1 analysts
FY2027
$-0.93
$-0.98–$-0.88
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Esther Rajavelu
Sector
Healthcare
Industry
Biotechnology
Employees
25
Beta
1.56
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-5.06
sperotherapeutics.com